Portal login

Publications

Publications Highlight

Highlights

Dynamics of Noninvasive Tests (NITs) – LIVERFASt, FIB-4 and Vibration-Controlled Transient Elastography (VCTE, FibroScan), During Monitoring Therapy with Resmetirom (RT) in Patients with MASH

LIVERFASt Outperforms FIB-4, in Sequential Combination with Vibration-Controlled Transient Elastography (VCTE) for Identifying ≥F3 Stages in Patients with MASLD Including Patients with Type 2 Diabetes (T2DM)

Publications

Read our selected publications

Dynamics of Noninvasive Tests (NITs) – LIVERFASt, FIB-4 and Vibration-Controlled Transient Elastography (VCTE, FibroScan), During Monitoring Therapy with Resmetirom (RT) in Patients with MASH

LIVERFASt Outperforms FIB-4, in Sequential Combination with Vibration-Controlled Transient Elastography (VCTE) for Identifying ≥F3 Stages in Patients with MASLD Including Patients with Type 2 Diabetes (T2DM)

Combination of LIVERfASt (LF) & Liver Stiffness Measurement (LSM) using Fibroscanoutperforms FIB-4 & LSM, for the identification of MASLD advanced fibrosis (AF) inpatients with type 2 diabetes (T2D)

LIVERFASt (L-FAST) identifies advanced (F3F4, AF) and clinically significant fibrosis (F2-F4, CSF) especially well with Fibroscan in MASLD patients (pts) from a tertiary hepatology center

Non-invasive initiation and monitoring of the therapy with TNR-beta agonist resmetirom (RT) using LiverFast, FIB-4 and vibration-controlled transient elastography (VCTE, FibroScan) in patients with MASH

LIVERFASt (L-FAST) identifies advanced (F3F4, AF) and clinically significant fibrosis (F2-F4, CSF) especially well with Fibroscan in MASLD patients (pts) from a tertiary hepatology center

Diagnostic Performance of LIVERFASt as a Non-invasive Liver Fibrosis Test: Data from Three Cohorts of Patients with Metabolic Dysfunction-associated Steatotic Liver Disease

Comparison of the prevalence of advanced fibrosis (AF) using two combinations Liver stiffness measurement (LSM or VCTE Fibroscan) along with LiverSTAT (LST) or FIB-4 in a prospective chronic liver diseases (CLD) cohort

The utility of noninvasive tests (NITs) -LIVERFASt, FIB4 and VCTE (Fibroscan) - in the initiation and monitoring of the therapy with TNR-beta agonist (resmetirom) in MASH patients

Retrospective cross sectional evaluation of the LIVERFASt Test for staging liver fibrosis in MASLD patients in NIDDK studies’ populations using liver biopsy

Application of LIVERFASt to Predict Steatosis in Chronic Hepatitis B Patients with Metabolic Syndrome

Comparison of the prevalence of advanced fibrosis (AF) using two combinations Liver stiffness measurement (LSM or VCTE Fibroscan) along with LiverSTAT (LST) or FIB-4 in a prospective chronic liver diseases (CLD) cohort

Application of LIVERFASt Biomarkers to Evaluate Longitudinal Hepatic Fibrosis and Inflammation after HCV cure